神経変性疾患治療薬市場分析と予測：2007年

Abstract

With the recent Alzheimer' s Association International Conference suggesting a new era of hope for sufferers of the illness, drug trials have shown some enlightening discoveries.

But Alzheimer' s isn' t the only neurodegenerative disease and drug possibilities in this market continue to expand. Visiongain reveal that the market value for the Neurodegenerative market was worth over $16 billion in 2006, with revenues growth anticipated to exceed $18 billion in 2007. But what will it be in 2012? This report will tell you.

This report provides comprehensive information on the neurodegenerative diseases; Parkinson' s Disease, Alzheimer' s Disease, Multiple Sclerosis and Neuropathic pain. The report also covers rare genetic disorders-Huntington disease, Amyotrophic Lateral Sclerosis a niche market disease classification and also Prion diseases.

The report tackles how the significant rise in the growing population age "Baby Boom" generation, paralleled with longevity across the globe will be a major catalyst for the pharmaceutical/health care sector revenue growth in the long-term. It also analyses periods of sustained revenue growth, during 2007-2012, and how expectant patent expirations on some major blockbuster drugs with strong market shares will boost revenues in the generics market. The neurodegenerative report also sheds significant emphasis on the financial burden of the neurodegenerative diseases on national healthcares services.

Advancement in innovation in the global pharmaceutical and healthcare sector are expected to spiral global annual earnings for the major market leaders including Biogen Idec, Elan, Eli Lilly, Novartis and Pfizer.

The Visiongain Neurodegenerative Market report looks at a broad spectrum of therapies during disease treatment, including;

• Biogen Idec and Elan' s Tysabri for remitting relapsing Multiple Sclerosis
• GW' s Cannabinoid product Sativex for Multiple Sclerosis
• Eli Lilly' s Cymbalta and Pfizer' s Lyrica indication for Neuropathic pain relief.

The report answers questions such as:

• In the next 5 years what will be the successful drugs
• Is stem cell research the answer for these diseases?
• Which of the current therapies show the greatest revenue generation potential?
• How will new drug development technologies impact on neuro disorders?

Visiongain' s, Global Neurodegenerative Market Reports provides a rich insight on current research underway globally by leading industries in pharmaceutical/ Biotech sector coupled with ,unbiased market forecast, affected by views of Healthcare regulatory authorities.

Visiongain' s Global Neurodegenerative Markets provides solutions to questions search as;

• Which regions have the highest prevalence of these diseases today and by 2020?
• What market share is accounted for by individual diseases in the neurodegenerative market?
• What is the global cost of neurodegenerative diseases and the significant market shares?
• How much the 2007 neurodegenerative market is to be valued at and what it will be worth by 2012?
• Which are the market leaders in this class of therapy?
• What are the current approved therapies in the market and are they more effective than present treatments?
• Which first line drugs will be coming off patent by 2012 and what are implications to the market?
• Which drugs have been withdrawn from the neurodegenerative market?
• Which molecules are currently in the pipelines that are deemed to answer unmet therapeutic needs in the future?

Why You Must Buy This Report:

Visiongain' s, Global Neurodegenerative Market Report, provides up-to-date analysis of present and future market illustrated by substantial number of charts and figures. It also discusses strategies employed by key players in the industries. This is a must buy report, as it will provide you with useful information on business opportunities in the big and niche markets.

The revenue forecasts generated in this report are exclusive to this report and are determined by the market, its future prospects in terms of patent protection, generic competition, life-cycle management, licensing agreements and market activity. With in-depth primary and secondary research, the forecasts run up to 2012. It will provide you with information on the dynamics of the Neurodegenerative Disease Market, and its operation until that time.

More key questions that this report answers:

• What is the potential population treatment in the major global markets up to 2012?
• Which are the main therapeutic agents dictating the pace of the market?
• What companies are the major drivers in the market?
• What is the present market activity and are the therapies effective?
• What is the envisaged Market activity in 2012?
• How will the growing population size affect the market in 2012 (Is big pharma up to the challenge?) How condensed is the Neurodegenerative drug pipeline?
• What is big pharma doing to narrow unmet therapeutic demands?

Unique benefits to you when you order this report:

• Immediate access through our exclusive Reading Room
• You can access your report whichever country you are in without using hard drive space
• Primary research throughout. You will not find this information anywhere else
• Report stored in your reading room for ever
• Full searchable report when you buy the company or corporate editions
• Copies can be printed off for offline reading
• Packed with charts, analysis, figures, graphs and tables

Table of Contents

Chapter 1. Introducing the World Market for Neurodegenerative Disorders

• Chart 1.1 Total Revenues for Neurodegenerative Diseases ($m), 2007-2012
• Table 1.1 Overall Forecast for Neurodegenerative Diseases ($m), 2007-2012
• Chart 1.2 Market Share (%) of Neurodegenerative Diseases, 2006
• Chart 1.3 Market Share (%) of Neurodegenerative Diseases,2007

Chapter 2. Neurodegenerative Disorders

• 2.1 Introduction to Neurodegenerative Disorders
• 2.2 What the Global Market for Neurodegenerative Disorders tells us
• 2.3 Focus of the report

Chapter 3. Parkinson' s Disease

• 3.1 Parkinson' s Disease Overview
• 3.2 Symptoms and Differential Diagnosis
  • 3.2.1 Tremors
  • 3.2.2 Bradykinesia
  • 3.2.3 Diagnosis
• 3.3 What are the Risk Factors?
  • 3.3.1 Age
  • 3.3.2 A possible genetic basis to PD
  • 3.3.3 Men are more likely to develop PD
  • 3.3.4 Pesticides and Herbicides influence PD Development
  • 3.3.5 Reduced Oestrogen Levels increase the risk of PD
  • 3.3.6 Reduced Folate Levels Associated with PD
  • 3.3.7 Anti-oxidants
• 3.4 Demographics of PD
  • Chart 3.1 Projected Global Parkinson' s Disease growth 2005- 2030 (m)
  • Chart 3.2 Projected Parkinson' s Disease Growth In 2030, by Region (%)
  • Chart 3.3 Parkinson' s Disease Global Market Share in 2005
• 3.5 Financial Burden of PD
• 3.6 Pathophysiology of PD
• 3.7 The Market Profile of PD
• 3.8 Current Pharmaceutical Therapies of PD
  • Table 3.1 Current pharmaceutical therapies available for Parkinson' s Disease
  • Table 3.2 Other Medications available for Parkinson' s Disease
• 3.9 Dopamine Precursors as the Standard Treatments for PD
  • 3.9.1 Sinemet (Co-Careldopa)
    • Chart 3.4 Sinemet Revenue forecast 2007-2012
    • Table 3.3 Sinemet Revenue Forecast for 2007-2012
  • 3.9.2 Madopar (Co-benelopa)
    • Chart 3.5 Madopar Revenue forecast 2007-2012
    • Table 3.4 Madopar Revenue Forecast for 2007-2012
  • 3.9.3 Carbidopa and Benserazide
• 3.10 Dopamine Agonists as Treatments for PD
  • 3.10.1 Ergot-Alkaloid-Based Agents
  • 3.10.2 Parlodel (Bromocriptine)
    • Chart 3.6 Parlodel Revenue 2001-2006
  • 3.10.3 Dopergine (Lisuride) is Superior to Parlodel
  • 3.10.4 Permax (Pergolide)
    • Chart 3.7 Permax Revenue before withdrawal
• 3.11 Apomorphine as Additional Relief for PD Sufferers
  • 3.11.1 Requip (Ropinirole)
    • Chart 3.8 Requip Revenue forecast 2007-2012
    • Table 3.5 Sinemet Revenue Forecast for 2007-2012
  • 3.11.2 Sifrol/Mirapexin (Pramipexole) is the Most Successful Drug in PD
    • Chart 3.9 Sifrol Revenue forecast 2007-2012
    • Table 3.6 Sifrol Revenue Forecast for 2007-2012
• 3.12 N-Methyl-D-Asparate Receptor Antagonists (NMDA)
• 3.13 Symmetrel (Amantadine)
• 3.14 AMPA alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid Receptor Antagonist
  • 3.14.1 Talampanel
• 3.15 COMT (Catechol-O-methyl transferase) Inhibitors
  • 3.15.1 Tasmar (Tolcapone) as an Adjunct Therapy
  • 3.15.2 Comtess (Entacapone) to Aid PD Treatment
    • Chart 3.10 Comtan Revenue forecast 2007-2012
    • Table 3.7 Comtan Revenue Forecast for 2007-2012
    • Chart 3.11 Comtess Revenue forecast 2007-2012
    • Table 3.8 Comtess Revenue Forecast for 2007-2012
• 3.16 Dopamine and COMT combined
  • 3.16.1 Stalevo - the combination therapy
    • Chart 3.12 Stalevo Revenue forecast 2007-2012
    • Table 3.9 Stalevo Revenue Forecast for 2007-2012
• 3.17 Anticholinergics (Antimuscarinic drugs)
  • 3.17.1 Congentin (benzatropine mesilate)
  • 3.17.2 Artane (Trihexyphenidyl) to Control Common Symptoms
• 3.18 Antihistamines and Antidepressants Can aid PD Symptoms?
• 3.19 Monoamine Oxidase B Inhibitors
  • 3.19.1 Deprenyl (Selegeline)
• 3.20 The World Market for PD Drugs in will show significant growth to 2012
  • Table 3.10 Revenue forecasts for selected PD drugs 2007-2012
  • Chart 3.13 Total Global Parkinson' s Disease market forecast 2007-2012
  • Table 3.11 Total Global Parkinson' s Disease market forecast 2007-2012
• 3.21 Surgical Therapy is not a Popular Treatment of PD
  • 3.21.1 Thalamotomy only used to Reduce Tremors
  • 3.21.2 Pallidotomy is becoming more popular as a Treatment for PD
  • 3.21.3 Deep Brain Stimulation aids in Tremor Reduction
• 3.22 Emerging therapies for Parkinson' s Disease
  • 3.22.1 ALS Drug, Rilutek (Riluzole), to Help PD Patients
  • 3.22.2 HD Treatment, Remacemide(Remacemide hydrochloride), for PD
  • 3.22.3 Rasagiline
  • 3.22.4 Azilect (Rasagiline)
• 3.23 Other New Drugs in Development
  • 3.23.1 The process of Apoptosis in Parkinson' s Disease
  • 3.23.2 Pig Neuron Implantations as new Treatments for PD
  • 3.23.3 A Nerve Growth Promoter may have a Role in PD Treatment
  • 3.23.4 The Implantation of Dopamine Producing Cells as a Novel Therapy in PD
  • 3.23.5 GDNF Gene Therapy as a new Treatment Therapy
  • 3.23.6 Biogen Idec and Vernalis Phase II BIIB014 oral compound
  • 3.23.7 Subcutaneous drug delivery system underway for treatment of PD
  • 3.23.8 Neuroprotective agent PD 02 slows PD progression in phase II trials
  • 3.23.9 Newron' s safinamide effective in early and late-stage Parkinson' s disease
  • 3.23.10 Signalling Ret-receptors protect the live of nerve cells in the aging brain
  • 3.24.1 Parkinson' s patch approved in Europe for all stages of Parkinson' s disease
  • 3.24.2 Neurologix completes Phase I GAD gene therapy trial for Parkinson' s disease.
  • 3.24.3 Ceregene in a Phase I Neurturin gene therapy study
  • 3.24.4 Arundic acid an astrocyte modulating agent for PD
  • 3.24.5 Antioxidative properties of Vitamin E, C and health food
  • 3.24.6 Coenzyme Q10 potential antioxidant

Chapter 4. Alzheimer' s Disease

• 4.1 Introduction
• 4.2 Symptoms and Differential Diagnosis
• 4.2.1 Using brain scans to detect Alzheimer' s
• 4.3 The Risk Factors for AD
• 4.4 The Demographics for AD
  • Chart 4.1 Prevalence of Alzheimer' s Diseases
  • Chart 4.2 Prevalence of Alzheimer' s Diseases After Every Five Years
• 4.5 Financial Burden of AD
  • Chart 4.3 Projected Growth of Alzheimer' s Diseases in the USA by 2050 (m)
• 4.4 Global Sufferers of Alzheimer' s Diseases in 2005, 29.3 Million
  • Chart 4.5 Global Cost of Alzheimer' s Diseases, 2003-2005 ($m)
• 4.6 Type of Protein as a Cause for AD?
  • 4.6.1 Neuronal and Synaptic Loss of AD
  • 4.6.2 Chromosomal Mutations of AD
  • 4.6.3 Inflammation of AD
• 4.7 Current AD Pharmaceutical Drug Therapies
• 4.8 Acetylcholinesterase Drugs - How do you Treat Mild to Moderate AD?
  • 4.8.1 Cognex (Tacrine)
  • 4.8.2 Aricept (Donepezil hyrdochloride) - The leading drug choice for AD
  • 4.8.3 Excelon (Rivastigamine) - Popular Drug Therapy for AD
    • Table 4.1 Aricept Revenue forecast 2007-2012
    • Chart 4.7 Aricept Revenue forecast 2007-2012
  • 4.8.4 Reminyl (Galantamine) is a Minor Treatment for AD
• 4.9 Ebixa (Namenda) The Drug Treatments for Moderate to Severe AD
  • Chart 4.8 Reminyl revenue forecast 2007-2012
  • Table 4.2 Reminyl revenue forecast 2007-2012
• 4.10 Non steroidal anti-inflammatory drugs (NSAID)
• 4.11 The AD drug Market
  • Chart 4.10 Overall Market Forecast for Alzheimer' s Disease, 2007-2012
  • Table 4.4 Overall Market Forecast for Alzheimer' s Disease, 2007-2012
  • Chart 4.11 Market share for leading AD drugs, 2006
  • 4.11.1 Will the Major AD drugs continue to dominate the Market?
  • 4.11.4 Leading Cholinesterase inhibitors in the AD market
  • 4.11.5 US Dominates the World AD Market
• 4.12 Emerging Therapies for Alzheimer' s Disease
  • 4.12.1 Vitamin E (Antioxidants) for AD
  • 4.12.2 Research has revealed that Vitamin E, Vitamin C and other health foods do possess their oxidative properties.
  • 4.12.3 OTC Ginko Biloba May Slow AD Symptoms
  • 4.12.4 Oestrogen HRT May Protect Against AD
  • 4.12.5 Nicotine Replacement Therapy as a Potential Treatment for AD
• 4.13 Future Therapies for Alzheimer' s Disease will not overrule conventional drug therapies
• 4.14 The Future Market for Alzheimer' s Disease
• 4.15 Pipeline Drugs for AD
  • 4.15.1 PBT-1 (Coloquinol)
  • 4.15.2 Alzhemed
  • 4.15.3 Phenserine
  • 4.15.4 Allon Therapeutics' AL-108 and AL-208 to inhibit neuronal death
  • 4.15.5 Martek' s DHA reduces brain lesions in AD animal models
• 4.16 The Future of the AD Drug Market

Chapter 5. Multiple Sclerosis

• 5.1 Introduction
• 5.2 The different categories of MS
  • 5.2.1 Benign MS
  • 5.2.2 Relapse-remitting MS
  • 5.2.3 Primary progressive MS
  • 5.2.4 Secondary progressive
  • 5.2.5 Progressive relapsing MS
• 5.3 Symptoms and Differential Diagnosis
  • 5.3.1 Primary symptoms
  • 5.3.2 Secondary symptoms
  • 5.3.3 Tertiary symptoms
    • Table 5.1 Summary of Multiple Sclerosis Symptoms
  • 5.3.4 Diagnosis of MS
• 5.4 The Risk factors of MS
  • 5.4.1 Immunologic Factors
  • 5.4.2 Environmental Effects may influence MS Incidence
  • 5.4.3 The Viral Induction of MS is possible
  • 5.4.4 The Genetic Basis of MS Exists
  • 5.4.5 Hormones Presidspose Women to MS
• 5.5 The Demographics of MS
  • Chart 5.1 The Global Dermographics of MS,2007
• 5.6 Current Pharmaceutical Drug Therapies
• 5.7 Relapsing-Remitting MS
  • 5.7.1 Avonex (Interferon beta 1a) to Reduce Severity of MS
  • 5.7.2 Rebif (Interferon beta 1a)
  • 5.7.3 Betaseron (Interferon beta 1b)
  • 5.7.4 Copaxone (Glatiramer acetate)
• 5.8 Antineoplastic Drugs (Relapse-Remitting & Secondary progressive)
  • 5.8.1 Cancer Drug, Novantrone (Mixonatrone) Benefits MS Sufferers
    • Table 5.3 Novantrone revenue Forecast 2007-2012
    • Chart 5.3 Novantrone Revenue Forecast 2007-2012
• 5.9 Taxanes
  • 5.9.1 Taxol (paclitaxel)
• 5.10 Immunosuppressants - Secondary Progressive and Worsening Relapse-Remitting MS
  • 5.10.1 Imuran (Azathioprine)
  • 5.10.2 Sandimmune (Cyclosporine)
• 5.11 Corticosteroids
• 5.12 Muscle Relaxants
• 5.13 Market Analysis of Multiple Sclerosis
  • 5.13.1 Avonex remains the leading MS drug
    • Chart 5.4 Avonex revenue forecast 2007-2012
    • Table 5.4 Avonex revenue forecast 2007-2012
    • Chart 5.5 Copaxone revenue forecast 2007-2012
    • Table 5.5 Copaxone revenue forecast 2007-2012
    • Chart 5.6 Rebif Revenue Forecast, 2007-2012
    • Table 5.6 Rebif Revenue Forecast, 2007-2012
    • Chart 5.7 Betaferon revenue forecast 2007-2012
    • Table 5.7 Betaferon revenue forecast 2007-2012
    • Chart 5.8 Overall MS Market Forecast For 2007-2012
    • Table 5.8 Overall MS Market Forecast for 2007-2012
    • Table 5.9 Market Share of Major MS drugs 2005-2006
    • Chart 5.9 Market Share of Major MS drugs 2005-2006
  • 5.13.1 Current Drugs approved in the MS Market
    • 5.13.1.1 Elan /Biogen Idec Tysabri (natalizumab) for remitting relapse MS
    • 5.13.1.2 Tysbri will dominate MS market share during 2007-2012
      • Chart 5.10 Tysabri Revenue Forecast 2007-2012
      • Table 5.10 Tysabri Revenue Forecast 2007-2012
    • 5.13.1.3 GW Sativex Investigational Cannabis-Based Treatment for MS
• 5.14 Pipeline drugs
  • 5.14.1 Oral drugs development for MS
    • 5.14.1.1 Serono' s Mylinax (oral formulation)
    • 5.14.1.2 Novartis' s Fingolimod (FTY720)
    • 5.14.1.3 Sanofi-Aventis' s Teriflunomide
    • 5.14.1.4 Pfizer' s Lipitor (atorvastin)
    • 5.14.1.5 Active Biotech' s Laquinimod
  • 5.14.2 Progressive forms of MS studies underway
    • 5.14.2.1 Genetech Rituxan
    • 5.14.2.2 Bayhill Therapeutics BHT-309
    • 5.14.2.3 BioMS synthetic fragment
    • 5.14.2.3 MS Society funded Oral against Inhaled cannabis study
  • 5.14.3 Other studies underway include extending the indications of therapies approved by the FDA to treat MS.
• 5.14. Leustat (Cladibrine)
• 5.15 Experimental Treatment for Multiple Sclerosis
  • 5.15.1 Gene Therapy
  • 5.15.2 Plasmapheresis (plasma exchange)
  • 5.15.3 Intravenous Immunoglobin (IVIg)
  • 5.15.4 Oligodendrocyte Implants

Chapter 6. Huntington' s Disease

• 6.1 Introduction
• 6.2 Aetiology of HD
• 6.3 Symptoms and Differential Diagnosis of HD
  • 6.3.1 Early Symptoms
  • 6.3.2 Advanced Symptoms
• 6.4 Demographics of HD
• 6.5 Pathophysiology of HD
• 6.6 Current Pharmacological Treatment for HD
• 6.7 Chorea Controlled by Benzodiazepines
• 6.8 Dopamine Antagonists can help HD patients
  • Chart 6.1 Haldol Revenue 2003-2006
  • 6.8.1 Cannabinoids to Ease Symptoms of HD
• 6.9 Monoamine-depleting agents
  • Chart 6.2 Nitoman Revenue Forecast,2007-2012
  • Table 6.1 Nitoman Revenue Forecast,2007-2012
• 6.10 Prospects for Future Treatment
  • 6.10.1 Cystamine to reduce symptoms
  • 6.10.2 HDAC Inhibitors may serve as a potential cure for HD
  • 6.10.3 Avicena HD-02 novel candidate for HD
  • 6.10.4 Ubiquitin proteasome systems in HD
  • 6.10.5 Other potential HD therapies
  • 6.10.6 Riluzole (Rilutek)
  • 6.10.7 Antioxidants contribute to future treatment of HD
  • 6.11.0 The Case for Stem Cells
  • 6.11.1 Working on Neurotrophic Factors for HD
  • 6.11.2 Regeneron and Medtronic collaborate on Axokine
  • 6.11.3 Evaluation of SIRT1 Inhibitors in Huntington' s disease
  • 6.11.4 Antibiotic Minocycline may have a Role in HD Treatment
  • 6.11.5 Amarin Miraxion in HD
  • 6.11.6 Gene Therapy model in HD
• 6.12 Market opportunities in HD

Chapter 7. Amyotrophic Lateral Sclerosis

• 7.1 Introduction
• 7.2 The Progression of ALS
• 7.3 Risk Factors of ALS
• 7.4 The Diagnosis of ALS
• 7.5 The Demographic Impact of ALS
  • Chart 7.1 Global Dermographics of ALS
• 7.6 What are the Treatment Options for ALS?
  • 7.6.1 Rilutek (riluzole)
    • Chart 7.2 Riluzole Revenue Forecast,2007-2012
    • Table 7.1 Riluzole Revenue Forecast,2007-2012
  • 7.6.2 The Pharmacological Treatment for Symptom Relief of ALS
  • 7.6.3 Neurontin (Gabapentin)
  • 7.6.4 Topamax (Topiramate)
• 7.7 Pipeline Drugs for ALS
  • 7.7.1 Creatine Monohydrate
  • 7.7.2 CEP 1347 (Cephalon' s mixed-lineage kinase inhibitor)
  • 7.7.3 Xaliproden Hydrochloride to Regenerate NF
• 7.8 Can a Cure for ALS be Found?
  • 7.8.1 Neurotrophic Factors
  • 7.8.2 The Role of Apoptosis in ALS
  • 7.8.3 Biological Markers for ALS
  • 7.8.4 Gene Research in ALS
  • 7.8.5 The Antibiotic Minocycline may have a Role in ALS Treatment
  • 7.8.6 Cox-2 (Nimesulide)

Chapter 8. Neuropathies

• 8.1 Introduction
• 8.2 Causes of Neuropathy
• 8.3 The Symptoms of Neuropathy
• 8.4 Who is at Risk?
• 8.5 Diagnosis of Neuropathy
• 8.6 The Classifications of Neuropathy
  • 8.6.1 Diabetic Neuropathy
  • 8.6.2 Auto-immune Disease and its Relationship with Neuropathic Pain
  • 8.6.3 Chemotherapy-Induced Neuropathy
  • 8.6.4 Drug-Related Neuropathy
• 8.7 The Societal Impact of Neuropathy
  • Chart 8.1 Global Demographics of Neuropathetic Pain
• 8.8 The Cost of Neuropathic Pain
• 8.9 The Current Treatment of Neuropathy
• 8.10 Non-pharmaceutical Treatments and Therapies for Neuropathic Pain
  • 8.11.1 The Major Current Pharmaceutical Treatment for Neuropathy
  • 8.11.2 Pfizer' s Lyrica an approved therapy for peripheral neuropathic pain
    • Table 8.1 Lyrica Revenue Forecast, 2007-2012
    • Chart 8.2 Lyrica Revenue Forecast, 2007-2012
  • 8.11.3 Lilly' s Cymbalta an approved therapy for peripheral diabetic neuropathy (PDN)
    • Table 8.2 Cymbalta Revenue Forecast,2007-2012
    • Chart 8.3 Cymbalta Revenue Forecast,2007-2012
    • Chart 8.4 Teva (Neurontin) Revenue Forecast, 2007-2012
    • Chart 8.5 Pfizer (Neurontin) Revenue Forecast, 2007-2012
    • Chart 8.6 Actavis (Neurontin) Revenue Forecast,2007-2012
    • Chart 8.7 Apotex (Neurontin) Revenue Forecast,2007-2012
    • Chart 8.8 Pharmascience (Neurontin) Revenue Forecast,2007-2012
    • Table 8.3 Neuopathy Revenue Forecast,2007-2012
    • Chart 8.9 Neuropathy Revenue Forecast,2007-2012
  • 8.12.1 Pain relievers
  • 8.12.2 Antidepressants
    • Table 8.4 Common Antidepressants Used In Treating Neuropathiese
  • 8.12.3 Anticonvulsants
  • 8.12.4 Antiarrhythmics
  • 8.12.5 Analgesics
  • 8.12.6 Opioids Maintaining Relief for Neuropathy
  • 8.12.7 Morphine
  • 8.12.8 Duragesic (Fentanyl)
  • 8.12.9 Oxycontin (Oxycodone)
• 8.13 Other Drugs Used in Neuropathies
  • 8.13.1 Mexitil (Mexiletine)
  • 8.13.2 Methycobal (Mecobalamin)
  • 8.13.3 Tramadol
• 8.14 Current Developments: New Anticonvulsants
  • 8.14.1 Topamax (Topiramate) - An indication of Topamax in Neuropathic Pain will see Revenues Rise
  • 8.14.2 Lamictal (Lamotrigine) - Anti-Epileptic Lamictal may be Indicated for Neuropathic Pain
  • 8.14.3 Keppra (Levetiracetam)
  • 8.15.1 Thioctic Acid
  • 8.15.2 Topical QR-333 a potential compound for diabetic neuropathy
  • 8.15.3 Allon Therapeutics AL-108 and AL-208 Molecules to inhibit neuronal death
  • 8.15.4 Biovitrum commence Phase II trials
  • 8.15.5 Brane Potential Blockbuster drug
• 8.16 Growth Factors may have a Role in Neuropathic Pain
• 8.17 NMDA Antagonists
  • Table 8.4 Other Current Developments in Neuropathic Drugs, 2007

Chapter 9. Prion Diseases

• 9.1 Introduction
• 9.2 CJD
  • 9.2.1 What is it?
  • 9.2.2 The Aetiology of CJD
• 9.3 Varying Types of CJD
  • 9.3.1 Sporadic or classical CJD
  • 9.3.2 Hereditary or familial CJD
  • 9.3.3 Acquired or iatrogenic aCJD
  • 9.3.4 (Variant) vCJD
    • Table 9.1 Number of suspect cases referred to CJD surveillance unit in Edinburgh and other reported cases in the UK
• 9.4 Demographics of CJD
• 9.5 Symptoms of CJD
  • 9.5.1 Initial symptoms
  • 9.5.2 Progressive symptoms
  • 9.5.3 End-stage symptoms
• 9.6 Diagnosis of CJD
• 9.7 Treatments of CJD
• 9.8 The Political issues attached to CJD
• 9.9 Gerstmann-Straussler-Scheinker Syndrome (GSS)
  • 9.9.1 What is it?
  • 9.9.2 Aetiology of GSS
  • 9.9.3 Symptoms of GSS
  • 9.9.4 Demographics of GSS
• 9.10 FFI
  • 9.10.1 What is it?
  • 9.10.2 Aetiology of FFI
  • 9.10.3 Symptoms of FFI
  • 9.10.4 Diagnosis of FFI
  • 9.10.5 Demographics of FFI
  • 9.10.6 Stages of FFI
  • 9.10.7 Treatment
• 9.11 Kuru
  • 9.11.1 What is it?
  • 9.11.2 Symptoms of Kuru
  • 9.11.5 Demographics of Kuru
  • 9.11.6 Treatment of Kuru
  • 9.11.7 Future Research for Kuru
• 9.12 Alper' s Syndrome
  • 9.12.1 What is it?
  • 9.12.2 Aetiology of Alper' s
  • 9.12.3 Symptoms of Alper' s
  • 9.12.4 Primary symptoms of Alper' s
  • 9.12.5 Secondary symptoms of Alper' s
  • 9.12.6 Treatment for Alper' s Syndrome
  • 9.12.7 Prognosis of Alper' s syndrome
  • 9.12.8 What research is being done?

Chapter 10. Summary of the Neurodegenerative Market

Organisation Listed

• Abbott Laboratories
• Actavis
• Active Biotech
• Alliance
• Allon Therapeutics
• Alpharma
• Alza
• Amarin Corporation
• Amgen
• Apotex
• Astellas
• AstraZeneca
• Avicena
• Bayhill Therapeutics
• Berlex
• Biogen Idec
• BioMS Medical
• Biovitrium
• Boehringer Ingelheim
• Brane Discovery
• Bristol-Myers Squib
• Britannia
• Buck Institute for Age Research
• Caraco Pharmaceutical Laboratories
• Cephalon
• Ceregene
• Chiesi
• Cognetix
• Core Pharma
• DepoMed
• Diacin
• Elan
• Eli Lilly
• Elixir Pharmaceuticals
• EMEA
• Endo Pharmaceuticals
• EpiCept
• Esai
• First Horizon
• Food and Drug Administration
• Forest
• Genentech
• Genzyme
• GSK
• Guilford
• GW Pharmaceuticals
• H Lundbeck
• Impax
• IVAX
• Janssen-Cilag
• Johnson & Johnson' s
• Journal of Alzheimer' s & Dementia
• Journal of Neurochemistry
• Karoliska Institute
• Labopharm
• Max Planck Institute of Neurobiology
• Medtronic
• Merck & Co
• MHRA
• MS Society
• MSD
• Mutual Pharmaceutical
• Myelos Neuroscience
• Mylan
• National Academy of Sciences
• National Institute of Aging
• National Institute of Neurodegenerative Diseases and Stroke
• National Prion Clinic
• Neo Therapeutics
• Neurobitotic
• Neurochem
• NeurogesX
• Neurologix
• NeuroSearch
• Newron
• Novartis
• Orion
• Otsuka
• Pharmaceuticals
• PCC Naturals
• Pfizer Pharmacia (Pfizer)
• PharmaNova
• Pharmascience
• Polymun
• Prana Technology
• Prestwick
• Prometheus
• Purdue
• Pharma
• Quigley
• Pharma
• Regeneron
• Rhone
• Poulenc
• Rorer
• Rinat
• Roche
• Rorer Pharm
• Sanochemia
• Sanofi-Aventis
• SantoSolve
• Schering (Bayer Schering)
• Schwarz Pharma
• Serono
• Shire
• Siena Biotech
• Stanford University
• Takeda Chemical
• Teva
• The New England Journal of Medicine
• UCB Pharma
• UK medical research council
• University of Roches
• Valeant
• Vernalis
• Vertex
• VistaGen
• WHO
• Wyeth
• Xenoport